BMS-986497
Near Add Your Location
Accepting patients
BMS-986497 (ORM-6151)
Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- GSPT1 Degrader
- CD33
- Phase 1
Showing 1-1 of 1